Neogen Corporation (NEOG)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 4
Do Nothing: fundamentalScore is 2 (below required floor of 3); strategy requires fundamentalScore ≥ 3 before any bullish entry.
Company overview
Neogen Corporation develops and distributes products for food quality and animal health. Its Food Safety division offers diagnostic test kits for detecting contaminants in food and feed. The Animal Safety division provides veterinary instruments, pharmaceuticals, and genomics testing services.
Fundamental
weakNeogen's fundamentals show solid margins but declining revenue and slight unprofitability, with leverage and valuation concerns.
Mixed fundamentals: solid gross/EBITDA margins and positive operating cash flow, but revenue has been drifting lower and profitability remains slightly negative. Leverage and weak quantitative risk signals (Altman Z ~1.44, interest coverage below 1) combine with a not-cheap valuation (EV/EBITDA ~18; ~1.28% free-cash-flow yield) to keep this in “monitor” territory rather than a clear-value setup.
Sentiment
fairSentiment is mixed with positive post-earnings guidance but regulatory scrutiny overhangs.
Recent coverage skewed modestly positive after NEOG’s Q4/FY2026 results and FY2027 guidance (announced 2026-07-30), but ongoing antitrust scrutiny around the Zoetis–Neogen genomics business deal remains an unresolved bearish overhang; conflicting catalysts cap the qualitative score at 3. Sentiment delta vs the 30–90d baseline is indeterminate due to sparse baseline coverage, and no regulator-confirmed fraud/accounting investigations surfaced in the legal screens.
Technical
goodNeogen shows a strong technical setup with positive trend and momentum indicators.
NEOG is technically constructive: the 2026-08-07 close sits above SMA20/50/200, EMA9/21, and daily VWAP, while MACD remains above both signal and zero and ADX above 50 confirms a strong trend. The only drag is that price is still digesting beneath the 12.85 post-earnings high after a sharp 2026-07-30 range expansion, so the chart scores strong rather than elite.
You’re looking at 2026-08-08 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.